Le paludisme peut-il entraîner des complications graves ?
Oui, le paludisme peut causer des complications comme l'anémie sévère et le coma.
PaludismeComplications
#3
Comment gérer les complications transfusionnelles ?
La gestion inclut l'arrêt de la transfusion et le traitement des symptômes.
Réactions transfusionnellesTraitement médical
#4
Les complications sont-elles fréquentes avec le système Duffy ?
Les complications sont rares mais peuvent survenir en cas d'incompatibilité.
Système DuffyComplications médicales
#5
Quelles sont les conséquences d'une infection par le paludisme ?
Les conséquences incluent des défaillances organiques et des troubles neurologiques.
PaludismeConséquences
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour le paludisme ?
Les facteurs incluent vivre dans des zones endémiques et ne pas utiliser de protection.
PaludismeFacteurs de risque
#2
Les groupes sanguins rares sont-ils à risque ?
Oui, les groupes sanguins rares peuvent avoir un risque accru d'incompatibilité.
Groupes sanguinsRisque transfusionnel
#3
Les antécédents transfusionnels augmentent-ils le risque ?
Oui, des antécédents transfusionnels peuvent augmenter le risque de réactions.
Antécédents médicauxRéactions transfusionnelles
#4
Les femmes enceintes sont-elles à risque avec Duffy ?
Oui, les femmes enceintes peuvent avoir des complications liées au système Duffy.
GrossesseSystème Duffy
#5
Les voyageurs sont-ils à risque de paludisme ?
Oui, les voyageurs vers des zones à risque doivent prendre des précautions.
VoyagePaludisme
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Système Duffy : Questions médicales les plus fréquentes",
"headline": "Système Duffy : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Système Duffy : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-28",
"dateModified": "2025-04-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Système Duffy"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antigènes de groupe sanguin",
"url": "https://questionsmedicales.fr/mesh/D001789",
"about": {
"@type": "MedicalCondition",
"name": "Antigènes de groupe sanguin",
"code": {
"@type": "MedicalCode",
"code": "D001789",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050.705.230"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Système Duffy",
"alternateName": "Duffy Blood-Group System",
"code": {
"@type": "MedicalCode",
"code": "D004375",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Eugenia Lo",
"url": "https://questionsmedicales.fr/author/Eugenia%20Lo",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA."
}
},
{
"@type": "Person",
"name": "Delenasaw Yewhalaw",
"url": "https://questionsmedicales.fr/author/Delenasaw%20Yewhalaw",
"affiliation": {
"@type": "Organization",
"name": "Tropical and Infectious Diseases Research Center, Jimma University, Jimma, Ethiopia."
}
},
{
"@type": "Person",
"name": "Martin L Olsson",
"url": "https://questionsmedicales.fr/author/Martin%20L%20Olsson",
"affiliation": {
"@type": "Organization",
"name": "Medical Director of the Nordic Reference Laboratory for Genomic Blood Group Typing and Senior Consultant at the Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Region Skåne; Professor of Transfusion Medicine at the Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, and Vice-Dean at the Faculty of Medicine, Lund University."
}
},
{
"@type": "Person",
"name": "Rei Rama",
"url": "https://questionsmedicales.fr/author/Rei%20Rama",
"affiliation": {
"@type": "Organization",
"name": "University of North Carolina at Charlotte."
}
},
{
"@type": "Person",
"name": "Lilian Castilho",
"url": "https://questionsmedicales.fr/author/Lilian%20Castilho",
"affiliation": {
"@type": "Organization",
"name": "Professor and Researcher, Hemocentro Campinas, University of Campinas, Rua Carlos Chagas."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Serological and Molecular Study of the Duffy Blood Group among Malarial Endemic Region Residents in Brazil.",
"datePublished": "2022-08-05",
"url": "https://questionsmedicales.fr/article/35946633",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/0037-8682-0490-2021"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ancestral reconstruction and correlation of the frequencies of the hemoglobin S allele and the Duffy blood group alleles in human populations.",
"datePublished": "2022-11-14",
"url": "https://questionsmedicales.fr/article/36376949",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ajhb.23832"
}
},
{
"@type": "ScholarlyArticle",
"name": "Detection of Duffy blood group genotypes and submicroscopic Plasmodium infections using molecular diagnostic assays in febrile malaria patients.",
"datePublished": "2024-06-20",
"url": "https://questionsmedicales.fr/article/38902674",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12936-024-04875-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Duffy blood system and G6PD genetic variants in vivax malaria patients from Manaus, Amazonas, Brazil.",
"datePublished": "2022-05-08",
"url": "https://questionsmedicales.fr/article/35527254",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12936-022-04165-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Plasmodium vivax Malaria in Duffy-Positive Patients in Rwanda.",
"datePublished": "2023-08-07",
"url": "https://questionsmedicales.fr/article/37549894",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4269/ajtmh.23-0143"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Antigènes",
"item": "https://questionsmedicales.fr/mesh/D000941"
},
{
"@type": "ListItem",
"position": 4,
"name": "Isoantigènes",
"item": "https://questionsmedicales.fr/mesh/D007519"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antigènes de groupe sanguin",
"item": "https://questionsmedicales.fr/mesh/D001789"
},
{
"@type": "ListItem",
"position": 6,
"name": "Système Duffy",
"item": "https://questionsmedicales.fr/mesh/D004375"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Système Duffy - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Système Duffy",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-29",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Système Duffy",
"description": "Comment déterminer le groupe sanguin Duffy ?\nQuels tests sont utilisés pour le système Duffy ?\nLe groupe Duffy peut-il changer ?\nQuels sont les types de groupes Duffy ?\nComment le groupe Duffy affecte-t-il les transfusions ?",
"url": "https://questionsmedicales.fr/mesh/D004375#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Système Duffy",
"description": "Quels symptômes sont liés à l'incompatibilité Duffy ?\nL'absence d'antigène Duffy cause-t-elle des symptômes ?\nLes infections sont-elles liées au système Duffy ?\nComment le système Duffy affecte-t-il la santé ?\nY a-t-il des symptômes spécifiques au paludisme ?",
"url": "https://questionsmedicales.fr/mesh/D004375#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Système Duffy",
"description": "Comment prévenir les incompatibilités Duffy ?\nY a-t-il des mesures préventives pour le paludisme ?\nLes donneurs de sang doivent-ils être testés ?\nComment sensibiliser sur le système Duffy ?\nLes vaccinations aident-elles contre le paludisme ?",
"url": "https://questionsmedicales.fr/mesh/D004375#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Système Duffy",
"description": "Comment traiter une réaction transfusionnelle Duffy ?\nY a-t-il un traitement pour l'absence d'antigène Duffy ?\nComment prévenir les réactions transfusionnelles ?\nLe paludisme a-t-il un traitement spécifique ?\nLes transfusions peuvent-elles être évitées ?",
"url": "https://questionsmedicales.fr/mesh/D004375#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Système Duffy",
"description": "Quelles complications peuvent survenir après une transfusion ?\nLe paludisme peut-il entraîner des complications graves ?\nComment gérer les complications transfusionnelles ?\nLes complications sont-elles fréquentes avec le système Duffy ?\nQuelles sont les conséquences d'une infection par le paludisme ?",
"url": "https://questionsmedicales.fr/mesh/D004375#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Système Duffy",
"description": "Quels sont les facteurs de risque pour le paludisme ?\nLes groupes sanguins rares sont-ils à risque ?\nLes antécédents transfusionnels augmentent-ils le risque ?\nLes femmes enceintes sont-elles à risque avec Duffy ?\nLes voyageurs sont-ils à risque de paludisme ?",
"url": "https://questionsmedicales.fr/mesh/D004375#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment déterminer le groupe sanguin Duffy ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le groupe sanguin Duffy est déterminé par des tests sérologiques spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le système Duffy ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests d'agglutination et des tests d'anticorps sont utilisés pour le système Duffy."
}
},
{
"@type": "Question",
"name": "Le groupe Duffy peut-il changer ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, le groupe sanguin Duffy est déterminé génétiquement et ne change pas."
}
},
{
"@type": "Question",
"name": "Quels sont les types de groupes Duffy ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principaux groupes Duffy sont Fya et Fyb, avec des variations possibles."
}
},
{
"@type": "Question",
"name": "Comment le groupe Duffy affecte-t-il les transfusions ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une incompatibilité Duffy peut entraîner des réactions transfusionnelles."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à l'incompatibilité Duffy ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des réactions allergiques, fièvre et anémie."
}
},
{
"@type": "Question",
"name": "L'absence d'antigène Duffy cause-t-elle des symptômes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'absence d'antigène Duffy n'entraîne généralement pas de symptômes cliniques."
}
},
{
"@type": "Question",
"name": "Les infections sont-elles liées au système Duffy ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections, comme le paludisme, sont influencées par le système Duffy."
}
},
{
"@type": "Question",
"name": "Comment le système Duffy affecte-t-il la santé ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il influence la susceptibilité aux infections et les réactions transfusionnelles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques au paludisme ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes du paludisme incluent fièvre, frissons, et douleurs musculaires."
}
},
{
"@type": "Question",
"name": "Comment prévenir les incompatibilités Duffy ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par des tests sanguins avant toute transfusion."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives pour le paludisme ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'utilisation de moustiquaires et de répulsifs aide à prévenir le paludisme."
}
},
{
"@type": "Question",
"name": "Les donneurs de sang doivent-ils être testés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, tous les donneurs de sang doivent être testés pour les groupes sanguins."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser sur le système Duffy ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes d'information peuvent sensibiliser sur l'importance des tests sanguins."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles contre le paludisme ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines vaccinations peuvent réduire le risque d'infection par le paludisme."
}
},
{
"@type": "Question",
"name": "Comment traiter une réaction transfusionnelle Duffy ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'arrêt de la transfusion et la gestion des symptômes."
}
},
{
"@type": "Question",
"name": "Y a-t-il un traitement pour l'absence d'antigène Duffy ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de traitement nécessaire pour l'absence d'antigène Duffy."
}
},
{
"@type": "Question",
"name": "Comment prévenir les réactions transfusionnelles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par des tests de compatibilité rigoureux avant transfusion."
}
},
{
"@type": "Question",
"name": "Le paludisme a-t-il un traitement spécifique ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le paludisme est traité avec des antipaludiques comme la chloroquine."
}
},
{
"@type": "Question",
"name": "Les transfusions peuvent-elles être évitées ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des alternatives comme les médicaments ou les transfusions autologues peuvent être utilisées."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une transfusion ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des réactions allergiques, hémolyse et choc transfusionnel."
}
},
{
"@type": "Question",
"name": "Le paludisme peut-il entraîner des complications graves ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le paludisme peut causer des complications comme l'anémie sévère et le coma."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications transfusionnelles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut l'arrêt de la transfusion et le traitement des symptômes."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes avec le système Duffy ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares mais peuvent survenir en cas d'incompatibilité."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une infection par le paludisme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les conséquences incluent des défaillances organiques et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour le paludisme ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent vivre dans des zones endémiques et ne pas utiliser de protection."
}
},
{
"@type": "Question",
"name": "Les groupes sanguins rares sont-ils à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les groupes sanguins rares peuvent avoir un risque accru d'incompatibilité."
}
},
{
"@type": "Question",
"name": "Les antécédents transfusionnels augmentent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents transfusionnels peuvent augmenter le risque de réactions."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes sont-elles à risque avec Duffy ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes enceintes peuvent avoir des complications liées au système Duffy."
}
},
{
"@type": "Question",
"name": "Les voyageurs sont-ils à risque de paludisme ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les voyageurs vers des zones à risque doivent prendre des précautions."
}
}
]
}
]
}
Medical Director of the Nordic Reference Laboratory for Genomic Blood Group Typing and Senior Consultant at the Department of Clinical Immunology and Transfusion Medicine, Office of Medical Services, Region Skåne; Professor of Transfusion Medicine at the Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, and Vice-Dean at the Faculty of Medicine, Lund University.
Immunohematology, Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Office for Medical Services , Akutgatan 8, SE-22185, Lund , Sweden.
Department of Pathology, Hale Building for Transformative Medicine, Brigham and Women's Hospital, Rm 8002L, 60 Fenwood Rd, Boston, MA, 02115, USA. wlane@bwh.harvard.edu.
Harvard Medical School, Boston, MA, USA. wlane@bwh.harvard.edu.
Associate Professor, Division of Hematology and Transfusion Medicine, Department of Laboratory Medicine, Lund University, and Technical Director of Immunohematology Laboratories, Department of Clinical Immunology and Transfusion Medicine, Office for Medical Services, Lund, Sweden.
The atypical chemokine receptor 1 (ACKR1) gene encodes the Duffy blood group antigens in two allelic forms: FY*A (FY*01) and FY*B (FY*02), which define the Fy(a+b-), Fy(a-b+), and Fy(a+b+) phenotypes....
We evaluated 250 residents from a Brazilian malarial endemic region (RsMR). All individuals were phenotyped for Fya and Fyb antigens and genotyped for FY*A, FY*B, FY*B SE , and FY*B weak alleles....
Among the 250 individuals, 209 (83.6%) reported previous malaria infection, and 41 (16.4%) did not. The Fy(a+b+) phenotype was present in 97/250 (38.8%), while the Fy(a-b-) was present in 7/250 (2.8%)...
We reported a low prevalence of the Fy(a-b-) in persons who had previously been infected with Plasmodium vivax (67.5%). We observed that 102/141 (72.3%) individuals expressing the Fyb antigen had a P....
Malaria is an important selective force for human genetic adaptation due to the sustained, lethal impact it has had on populations worldwide. High frequencies of both hemoglobin S and the null allele ...
A tree topology and the allelic frequencies reported in the literature for the 24 populations were used. The ancestral frequencies for the two alleles were reconstructed using the maximum likelihood m...
For both alleles, a correspondence was found in the reconstruction of the ancestral frequencies, and a significant statistical correlation (p = .001) was observed between the S and FYB...
These results provide evidence of an epistatic relationship between the two alleles, which may influence the fitness of the individuals who present with them when they are subjected to a selective for...
Malaria remains a severe parasitic disease, posing a significant threat to public health and hindering economic development in sub-Saharan Africa. Ethiopia, a malaria endemic country, is facing a resu...
Three hundred febrile patients visiting four health facilities in Jimma town of southwestern Ethiopia were randomly selected during the malaria transmission season (Apr-Oct). Sociodemographic informat...
The Plasmodium infection rate by qPCR was 16% (48/300) among febrile patients, of which 19 (39.6%) were P. vivax, 25 (52.1%) were P. falciparum, and 4 (8.3%) were mixed (P. vivax and P. falciparum) in...
The present study revealed a high prevalence of submicroscopic malaria infections. Plasmodium vivax infections in Duffy-negative individuals were not detected due to low parasitaemia. In this study, a...
Over a third of the world's population is at risk of Plasmodium vivax-induced malaria. The unique aspect of the parasite's biology and interactions with the human host make it harder to control and el...
Molecular genotyping of G6PD and Duffy variants was performed in 225 unrelated patients (97 with uncomplicated and 128 with severe vivax malaria) recruited at a Reference Centre for Infectious Disease...
The Duffy blood group system showed a phenotypic distribution Fy(a + b-) of 70 (31.1%), Fy(a + b +) 96 (42.7%), Fy(a-b +) 56 (24.9%) and Fy(a-b-) 1 (0.44%.) The genotype FY*A/FY*B was predominant in b...
A high prevalence of G6PD c202G > A and c.376A > G and Duffy variants is observed in Manaus, an endemic area for vivax malaria. In addition, this study reports for the first time the Duffy null phenot...
Plasmodium vivax is the second-most common malaria pathogen globally, but is considered very rare in the predominantly Duffy-negative sub-Saharan African population. In 259 malaria patients from highl...
Plasmodium vivax Duffy Binding Protein (PvDBP) is essential for interacting with Duffy antigen receptor for chemokines (DARC) on the surface of red blood cells to allow invasion. Earlier whole genome ...
Absolute neutrophil counts (ANCs) are used to determine cancer clinical trial (CCT) eligibility and systemic anticancer therapy (SACT) dose modifications. Duffy null-associated ANC (DANC) is a nonpath...
To investigate CCT exclusions and SACT dose modifications for ANC within the DANC reference range....
This cross-sectional study of contemporary CCTs and SACT regimens included adult, interventional, phase 3 CCTs for the 5 most prevalent cancers in the US and United Kingdom (prostate, breast, melanoma...
Cancer clinical trial exclusions and SACT regimen modifications....
Proportions of CCTs that exclude and SACT regimens that modify doses for individuals with an ANC within the DANC reference range....
For CCTs, 289 of 382 trials (75.7%) were eligible, of which 221 (76.5% [95% CI, 71.1%-81.2%]) excluded patients with ANC values within the DANC reference range. Colorectal CCTs had the highest (38 of ...
In this cross-sectional study, substantial proportions of CCTs excluded and SACT regimens modified doses for patients with ANCs in the DANC reference range. These practices structurally discriminate a...
Despite historical dogma that Duffy blood group negativity of human erythrocytes confers resistance to Plasmodium vivax blood stage infection, cases of P. vivax malaria and asymptomatic blood stage in...
Duffy-null phenotype-associated neutropenia was present in 77.7% of leukopenia/neutropenia referrals to our center in Detroit with a high prevalence in Yemeni (96.6%), African American (91%), and non-...
The interaction between the Plasmodium vivax Duffy-binding protein and the corresponding Duffy Antigen Receptor for Chemokines (DARC) is primarily responsible for the invasion of reticulocytes by P. v...
A cross-sectional study was conducted from February 2021 to September 2022 at five varying eco-epidemiological malaria endemic sites in Ethiopia. Outpatients who were diagnosed with P. vivax infection...
In total, 361 patients with P. vivax infection were included in the study. Patients with pure P. vivax infections accounted for 89.8% (324/361), while the remaining 10.2% (37/361) had mixed P. vivax/P...
This study confirms that Duffy-negativity does not provide complete protection against P. vivax infection. The development of P. vivax-specific elimination strategies, including alternative antimalari...